Plant listing · Roorkee, Haridwar district, Uttarakhand
Injectable Pharma Plant for Sale in Uttarakhand — Roorkee, ₹10 Crore
A three-block formulation facility with a sterile small-volume parenteral section, a separate beta-lactam section and a general non-beta-lactam section, on a 33,000 sq. ft. plot with about 42,000 sq. ft. of construction. Asking price ₹10 crore, against a stated bank liability of ₹6 crore.
Read this first: the plant is closed and its manufacturing licences have been surrendered. This is an asset and re-licensing play, not a going concern. Everything below is written on that basis.
At a glance
Facility overview
A dormant formulation unit in the Roorkee belt of Haridwar district, offered as an asset sale. What is being bought is land, building, plant, machinery and utilities — plus the work of getting licences issued afresh. The dosage-form spread is the unusual part: sterile injectables, beta-lactams and general orals under one boundary wall is a combination that is expensive to build and rarely comes up second-hand.
Scroll the table sideways if a column is cut off
| Parameter | Details |
|---|---|
| Location | Roorkee, Haridwar district, Uttarakhand — on the Roorkee–Dehradun road corridor |
| Plot area | 33,000 sq. ft. (approximately 3,066 sq. m.) |
| Constructed area | Approximately 42,000 sq. ft. across the formulation blocks and utility areas |
| Formulation blocks | Sterile block, non-beta-lactam block, beta-lactam block |
| Dosage forms previously approved | Liquid injections in ampoules and vials, dry powder injections, eye and ear drops, tablets coated and uncoated, hard gelatin capsules, oral dry powders, dry syrups |
| Licence status | Manufacturing licences surrendered — no subsisting licence at present |
| GMP certification | Previously held from the state authority; lapses with the licence it was issued against |
| Operating status | Closed. No current turnover, no customer base and no brands offered with the unit |
| Bank liability | Approximately ₹6 crore — treatment at closing not disclosed |
| Asking price | ₹10 crore |
| Enterprise value at the ask | ₹10 crore to ₹16 crore, depending entirely on who clears the ₹6 crore borrowing |
| Year of construction | Not disclosed |
| Land title | Freehold or leasehold status not disclosed |
Capacity
Blocks, dosage forms and rated output
Output figures below are the seller-stated rated capacity per eight-hour shift, recorded when the unit was running. Treat them as design capacity, not achieved throughput — actual output depends on machine condition, batch sizes and the product mix you licence.
Sterile preparations — small volume parenterals
The block that gives this listing its value. Liquid injections in ampoules and vials, dry powder injections, and eye and ear drops. A sterile area is the single most expensive thing to build from scratch, and the hardest to retro-fit into a building that was not designed for it.
Non-beta-lactam oral solids
Coated and uncoated tablets, hard gelatin capsules and oral dry powders. This is the block that carries a contract-manufacturing business while the sterile licence is being re-established, because it is the fastest of the three to bring back into approval.
Beta-lactam section
Stated as covering tablets, capsules, dry syrups and both liquid and dry injections. Beta-lactams must sit in separate dedicated facilities with an independent air-handling unit and proper pressure differential[1], so this section has to be physically and mechanically self-contained. Confirm on the approved plan that it is, because the original listing text placed this section and the non-beta-lactam section in the same numbered block.
Correction carried over from the original listing: the earlier version of this page listed the non-beta-lactam section and the beta-lactam section both as “Formulation Block-2”. That cannot be right — the two cannot share a block. Ask for the approved building plan and the AHU schematic, and confirm which physical structure each section occupies before you value the sterile capability.
Decision support
Is this the right unit for you?
Three questions decide whether this asset fits. Answer them and the verdict below updates. Nothing is stored or sent anywhere.
What do you actually intend to make?
How soon do you need your first commercial batch?
What are you buying it as?
Verdict
Answer the three questions above
The verdict is based only on what this listing discloses. It is a screening aid, not advice.
Decision support
Due diligence score
Scored on disclosed information only. A low score means evidence is missing, not that a weakness is proven — several of these move sharply once the seller opens the file.
Overall, disclosed information only
12 of 25 points. The debt treatment, the approved building plan and the licence history are the three documents that move this number most.
The critical path
What it takes to make this plant legal again
This is the part of the deal that decides the price. The listing describes the licences as surrendered and easily reactivated. There is no reactivation route in the Drugs and Cosmetics Rules for a surrendered manufacturing licence — manufacture requires a subsisting licence, so the route back is a fresh application and a fresh inspection.
Two applications, not one
The forms this site needs
The parenteral and eye-drop sections fall under Schedules C and C(1), which are applied for in Form 27[2]; the licence granted against it is Form 28. The tablet, capsule and oral powder sections fall outside those schedules and are applied for in Form 24[3], with Form 25 granted against it. A site with both needs both, and the beta-lactam sections need their own endorsement within them.
- Applications go to the State Licensing Authority in Uttarakhand, with a joint inspection before grant.
- Each product you intend to make must be separately endorsed on the licence — the previous product list does not carry over automatically.
- Ask for the surrender correspondence and the last inspection report before you model any timeline.
Cost you are underwriting
Where the restart money goes
None of this is in the ₹10 crore. Budget it separately and treat it as part of the price you are paying for the site.
- Condition survey first. Idle HVAC, purified water loops and sterile equipment degrade quickly. Get an engineer through the plant before you offer.
- Re-qualification. HVAC validation, water system qualification and equipment requalification for anything that has been standing.
- Documentation build. Site master file, SOP set, validation protocols and the quality system the inspection will be judged against.
- Working capital from takeover to first invoice, which on a closed unit is longer than buyers expect.
The upside of a surrendered licence: it is also why the asking price is what it is. You are not paying for goodwill, a customer book or a brand portfolio, because none is on offer. Price the site as land, building, plant and the sterile block — then decide separately what the restart is worth to you.
Location
Roorkee, and what changed in 2026
Roorkee is a city and municipal corporation in Haridwar district, Uttarakhand, roughly 30 km from Haridwar and about 65 km from Dehradun. The district is one of North India’s established formulation belts, and the practical value of the address is the ecosystem around it: packaging converters, excipient stockists, contract testing laboratories, engineering and HVAC contractors, and a workforce that has already worked inside GMP areas.
Connectivity
Materially better than when this unit closed
The Delhi–Dehradun Economic Corridor was inaugurated on 14 April 2026, running from Delhi through Baghpat, Baraut, Shamli and Saharanpur[4]. The corridor reduces the Delhi–Dehradun road distance to 210 km and the journey to around 2.5 hours, and a greenfield link runs from the corridor at Halgoa, Saharanpur to Bhadrabad, Haridwar[5].
- New Delhi: approximately 180 km by road, route-dependent.
- Dehradun: approximately 65 km · Haridwar: approximately 30 km.
- Rail: Roorkee station on the Delhi–Dehradun/Haridwar line.
- Air: Dehradun (Jolly Grant) is the nearest airport; Delhi is the nearest wide-body hub.
Correction
Two claims that did not survive checking
The earlier version of this page carried two location claims that a buyer should not rely on.
- “Roorkee district, Haridwar.” There is no Roorkee district. Roorkee is a city and tehsil within Haridwar district. Use the correct description in any document you sign.
- “Tax incentives and government subsidies available.” The Section 80-IC deduction that built this belt required manufacture to commence by 31 March 2012, for a maximum ten-year deduction[6]. That window is closed. Do not price an area-based tax holiday into this acquisition. Verify any current state incentive directly with the Uttarakhand industrial department before relying on it.
Plant and machinery
What is standing in the building
Equipment is listed by maker as supplied by the seller. Ages, models, serial numbers, hours run and the date the plant last operated have not been disclosed, and on an idle site those are the details that decide whether the machinery is an asset or a disposal cost.
Production
Processing and filling
- Tablet compression: Felcon, CIP Machinery, Falcon Machineries
- Capsule filling: Pam, Harrison
- Liquid injection filling lines: Amba Sales and Service, Vishwakarma Engineering
- Packaging: IMA, Pharmatech, Shrine Pacsy Systems, Mechem Engineering
Utilities
Services and support
- Boilers
- RO plant for water treatment
- Effluent treatment plant
- Air handling units
- Dehumidifiers
A sterile section needs more than an RO plant. Ask specifically about the purified water and water-for-injection systems, the distribution loop, the clean steam arrangement and the HVAC classification of the aseptic area.
Numbers
Investment snapshot
On a closed unit there is no turnover to build a multiple from, so the honest model runs the other way: total cash to get to first invoice, against the revenue you believe you can put through the plant. Everything below is marked for what it is.
Restart model
Test the deal against your own numbers
Every field is editable and every output comes from what you type, not from seller data. Work in lakh throughout — 100 lakh equals ₹1 crore.
Read this before using the numbers: the ₹10 crore ask, the ₹6 crore liability, the areas, the equipment list and the rated capacities are seller-provided and unaudited. The calculator works only on figures you enter. It ignores interest, depreciation, tax, stamp duty, transfer costs and the time value of money, and it is not a valuation, forecast or financial advice. Have a chartered accountant and a lawyer run the real numbers before you commit.
Before you sign
Buyer checklist
Tick items as you clear them. Nothing is stored or transmitted — the list resets when you reload the page.
Checklist progress
0 of 14 items cleared
Data quality
Five points that need clarification
- The debt treatment is the whole negotiation. A ₹10 crore ask with a ₹6 crore borrowing attached is either a ₹10 crore deal or a ₹16 crore deal. That is a 60 per cent swing on the headline number, and it is unanswered. Resolve it in writing, in the same conversation as the price.
- “Easy reactivation” overstates the position. A surrendered manufacturing licence is not reactivated. Fresh applications are required for both the Schedule C and C(1) sections and the general sections, each product has to be endorsed again, and a joint inspection sits at the end of the process. Ask for a realistic timeline in writing rather than an assurance.
- The block numbering contradicts itself. Beta-lactam and non-beta-lactam sections were both described as Formulation Block-2. Beta-lactams require separate dedicated facilities with independent air handling, so the two cannot share a block. Until the approved plan resolves this, treat the beta-lactam capability as unverified.
- Nobody has said how long it has been standing. Rated capacities from when the plant ran are only meaningful alongside the date it stopped. An HVAC system, a water loop and a sterile filling line that have been idle for three years are a different asset from ones idle for six months. This is the single most useful undisclosed fact on the page.
- The tax incentive claim does not survive checking. The area-based deduction that made this belt attractive required manufacture to commence by 31 March 2012. A buyer restarting this unit today cannot claim it. If a current state-level incentive applies, get it confirmed by the Uttarakhand industrial department in writing before it enters your model.
If you are weighing this against building new, run the numbers through the pharma plant setup cost calculator and the breakdown of what a new pharmaceutical manufacturing plant actually costs. Before a site visit, work through the pharma plant acquisition checklist.
FAQs
Questions buyers ask about this unit
Request the licence history, building plan and machinery list
Send an enquiry and we will share the documents that are available, the debt position as stated by the seller, and arrange a site visit at Roorkee. Independent verification and professional due diligence are recommended before any commitment.
References
- Ministry of Health and Family Welfare, Government of India. Schedule M, Drugs and Cosmetics Rules, 1945 — Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products, Part I paragraphs 3.2 and 8.2.2 (separate dedicated facilities for beta-lactam products; segregated or isolated production areas with independent air-handling unit and proper pressure differential). Available from: https://ipapharma.org/wp-content/uploads/2019/02/schedule-m-1.pdf. Accessed September 2026.
- Ministry of Health and Family Welfare, Government of India. Form 27 [See rule 75(1)], Drugs and Cosmetics Rules, 1945 — Application for grant or renewal of a licence to manufacture for sale or for distribution of drugs specified in Schedules C and C(1), excluding those specified in Part XB and Schedule X. Available from: https://drugscontrol.org/pdf/Form27.pdf. Accessed September 2026.
- Directorate of Health Services, Government of Himachal Pradesh. List of documents for the grant of drug manufacturing licence — Form 24 (Rule 69), application for grant or renewal of a licence to manufacture for sale or for distribution of drugs other than those specified in Schedules C, C(1) and X. Available from: https://dhsr.hp.gov.in/Files/Drugs%20Manufacturing%20License.pdf. Accessed September 2026.
- Press Information Bureau, Government of India. Prime Minister Shri Narendra Modi inaugurates Delhi–Dehradun Economic Corridor. Posted 14 April 2026. Available from: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2251855. Accessed September 2026.
- Press Information Bureau, Government of India. Backgrounder: Delhi–Dehradun Economic Corridor — corridor distance reduced from 235 km to 210 km, travel time reduced to around 2.5 hours, and a greenfield alignment connecting Halgoa, Saharanpur to Bhadrabad, Haridwar. December 2021. Available from: https://static.pib.gov.in/WriteReadData/specificdocs/documents/2021/dec/doc202112361.pdf. Accessed September 2026.
- Income-tax Act, 1961, section 80-IC — deduction available to undertakings in Himachal Pradesh and Uttarakhand that began manufacture between 7 January 2003 and 31 March 2012, at 100 per cent of profits for five years and 30 per cent for companies for the following five years. Accessed September 2026.
Listing details, areas, capacities, equipment, licence history, liabilities, inclusions, availability and commercial figures are supplied by the seller for enquiry purposes and must be independently verified. Regulatory status and licensing routes are subject to confirmation with the State Licensing Authority and change from time to time. Laafon Galaxy Pharmaceuticals acts as an introducer and does not warrant seller-supplied information. This content is not legal, regulatory, investment or financial advice.
